DSS Stock Overview
Operates in the product packaging, biotechnology, commercial lending, securities and investment management, alternative trading, and direct marketing businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DSS, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$3.47 |
| 52 Week Low | US$1.02 |
| Beta | 1.84 |
| 11 Month Change | -16.13% |
| 3 Month Change | -20.61% |
| 1 Year Change | -62.35% |
| 33 Year Change | -94.19% |
| 5 Year Change | -99.38% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| DSS | US Commercial Services | US Market | |
|---|---|---|---|
| 7D | -8.0% | -2.4% | -1.0% |
| 1Y | -62.3% | 32.6% | 30.3% |
Return vs Industry: DSS underperformed the US Commercial Services industry which returned 33.1% over the past year.
Return vs Market: DSS underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| DSS volatility | |
|---|---|
| DSS Average Weekly Movement | 8.9% |
| Commercial Services Industry Average Movement | 7.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DSS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DSS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 95 | Jason Grady | www.dssworld.com |
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, alternative trading, and direct marketing businesses. It manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. The company also invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza.
DSS, Inc. Fundamentals Summary
| DSS fundamental statistics | |
|---|---|
| Market cap | US$7.35m |
| Earnings (TTM) | -US$67.80m |
| Revenue (TTM) | US$25.02m |
0.3x
P/S Ratio-0.1x
P/E RatioIs DSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSS income statement (TTM) | |
|---|---|
| Revenue | US$25.02m |
| Cost of Revenue | US$25.50m |
| Gross Profit | -US$481.00k |
| Other Expenses | US$67.32m |
| Earnings | -US$67.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.59 |
| Gross Margin | -1.92% |
| Net Profit Margin | -270.98% |
| Debt/Equity Ratio | 82.3% |
How did DSS perform over the long term?
See historical performance and comparison